RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

Sefaxersen achieves 43% proteinuria reduction in Phase 3 IgA Nephropathy Study, targeting disease mechanisms beyond standard care in kidney disease treatment.

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

FDA approves subcutaneous SKYRIZI for Crohn's disease induction, allowing at-home treatment. Phase 3 data showed 74% of biologic-naive patients reached clinical ...

Tango Therapeutics updates vopimetostat Phase 1/2 Trial results in combination with RAS(ON) inhibitors. Full data available in SEC filing.

Medpace wins the SCRS Eagle Award for CRO for the second consecutive year, based on ratings from nearly 2,000 global research sites.

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction versus 17% on place ...

Perspective Therapeutics' lead-212 radiopharmaceutical shows responses in neuroendocrine tumor trial, with interim Phase 1/2a data presented at European nuclear ...

CluePoints returns as defending two-time winner in the Scrip Awards, shortlisted for Best Contract Research Organization category.

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...